# Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4
Ticker: ARQT
Company: Arcutis Biotherapeutics
Source: Arcutis Biotherapeutics
Published: 2026-05-08 20:00 EST
Original Source URL: https://investors.arcutis.com
## Summary

WESTLAKE VILLAGE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 269,000 restricted stock units of

## Article Body
WESTLAKE VILLAGE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 269,000 restricted stock units of
## Recent Company News
- 2026-06-03 12:00 EST — [New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology](https://biopharmsignal.com/news/ARQT/new-expert-consensus-provides-age-specific-guidance-for-improving-care-for-individuals-with-genital-psoriasis-published-in-the-american-journal-of-clinical-dermatology) — Source: Arcutis Biotherapeutics
- 2026-05-26 20:00 EST — [Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/ARQT/arcutis-management-to-present-at-goldman-sachs-47th-annual-global-healthcare-conference) — Source: Arcutis Biotherapeutics
- 2026-05-08 20:00 EST — [Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ARQT/arcutis-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Arcutis Biotherapeutics
- 2026-05-06 20:00 EST — [Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/ARQT/arcutis-announces-first-quarter-2026-financial-results-and-provides-business-update) — Source: Arcutis Biotherapeutics
- 2026-04-27 12:00 EST — [Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months](https://biopharmsignal.com/news/ARQT/arcutis-submits-supplemental-new-drug-application-to-the-fda-for-zoryver-roflumilast-cream-0-05-to-expand-indication-for-treatment-of-atopic-dermatitis-to-infants-down-to-3-months) — Source: Arcutis Biotherapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)